OGEN
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Oragenics completed activation of all three Australian Phase IIa trial sites, with patient enrollment underwayJul 8, 2026
- Oragenics activated a second site in its Phase IIa trial of ONP-002 for concussion and mild traumatic brain injuryMay 5, 2026
- Oragenics reported completion of 8 study drug doses in its Phase IIa trial of ONP-002 for mild traumatic brain injuryApr 20, 2026
- Oragenics dosed the first patient in a Phase 2a trial of ONP-002 for mild traumatic brain injuryApr 13, 2026
- Oragenics received HREC approval for a Phase IIa trial of ONP-002 to treat concussion and mild traumatic brain injury in AustraliaMar 10, 2026